Table I.

Patients’ Clinical Characteristics

Patient No.	Histological Subtype	Age (years)	Sex	Donor	Prior Tx (n)	Failed Prior ASCT	Disease Status Prior to Tx	Time from Dx to Tx (months)
1	AITL	51	F	MR	5	Yes	SD	22
2	PTCL-NOS	61	M	MUR	4	Yes	CR	29
3	PTCL-NOS	55	M	MUR	3	Yes	CR	27
4	T-PLL	59	M	MUR	3	No	PD	25
5	AITL	51	M	MUR	6	Yes	CR	25
6	PTCL-NOS	61	F	MR	8	Yes	PR	144
7	PTCL-NOS	25	M	MUR	1	No†	CR	8
8	CTCL-SS	61	M	MUR	7	No	PD	20
9	AITL	72	M	MR	3	No	PR	6
10	PTCL-NOS	57	F	MUR	4	No	PR	21
11	PTCL-NOS	58	M	MR	3	No	SD	22
12*	NKC-L/L	63	M	MR	1	No	CR	9
13	T-PLL	62	F	MR	2	No	PR	9
14	T-PLL	59	M	MUR	3	No	PR	50
15*	AITL	57	F	MUR	1	No	CR	6
16	ALCL	45	M	MR	4	Yes	CR	48
17*	PTCL-NOS	73	M	MUR	2	No	CR	6

Abbreviations: AITL=angioimmunoblastic T-cell lymphoma; ALCL=anaplastic large cell lymphoma; ASCT=autologous stem cell transplantation; CR=complete remission; MR=matched related; MRD=minimal residual disease; MUR=matched unrelated; NK-L/L=NK-cell leukaemia/lymphoma; PD=progressive disease; PR=partial remission; PTCL-NOS=peripheral T-cell lymphoma, not otherwise specified; CTCL-SS = Cutaneous T-cell Lymphoma-Sezary Syndrome; SD=stable disease; T-PLL=T-cell prolymphocytic leukaemia; Dx=diagnosis; Tx=therapy.

^*Received NMA HCT as part of the primary therapy due to poor-risk disease characteristics or histology.

^†ASCT was performed as part of planned tandem autologous-NMA allogeneic transplantation.